Avantor, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Avantor, Inc. (AVTR) reported Net Income (Loss) Available to Common Stockholders, Diluted of $43.30 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-04-29
- Avantor, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was $43.30M, a 32.87% decline year-over-year.
- Avantor, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was $52.40M, a 89.53% decline year-over-year.
- Avantor, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$711.80M, a 1331.49% decline year-over-year.
- Avantor, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-06-30 was $64.70M, a 30.36% decline year-over-year.
- Avantor, Inc. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$530.20M, a 174.52% decline from fiscal 2024.
- Avantor, Inc. net income (loss) available to common stockholders, diluted for fiscal 2024 was $711.50M, a 121.58% increase from fiscal 2023.
- Avantor, Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was $321.10M, a 53.23% decline from fiscal 2022.
- Avantor, Inc. net income (loss) available to common stockholders, diluted for fiscal 2022 was $686.50M, a 35.14% increase from fiscal 2021.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-03-31 | $43.30M 10-Q · filed 2026-04-29 | $95.70M derived: sum of 2 quarters · filed 2026-04-29 | -$616.10M derived: sum of 3 quarters · filed 2026-04-29 | -$551.40M derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-12-31 | $52.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$659.40M derived: sum of 2 quarters · filed 2026-02-11 | -$594.70M derived: sum of 3 quarters · filed 2026-02-11 | -$530.20M 10-K · filed 2026-02-11 |
| 2025-09-30 | -$711.80M 10-Q · filed 2025-10-29 | -$647.10M derived: sum of 2 quarters · filed 2025-10-29 | -$582.60M 10-Q · filed 2025-10-29 | -$82.20M derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-06-30 | $64.70M 10-Q · filed 2025-08-01 | $129.20M 10-Q · filed 2025-08-01 | $629.60M derived: sum of 3 quarters · filed 2026-04-29 | $687.40M derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-03-31 | $64.50M 10-Q · filed 2026-04-29 | $564.90M derived: sum of 2 quarters · filed 2026-04-29 | $622.70M derived: sum of 3 quarters · filed 2026-04-29 | $715.60M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $500.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $558.20M derived: sum of 2 quarters · filed 2026-02-11 | $651.10M derived: sum of 3 quarters · filed 2026-02-11 | $711.50M 10-K · filed 2026-02-11 |
| 2024-09-30 | $57.80M 10-Q · filed 2025-10-29 | $150.70M derived: sum of 2 quarters · filed 2025-10-29 | $211.10M 10-Q · filed 2025-10-29 | $309.60M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $92.90M 10-Q · filed 2025-08-01 | $153.30M 10-Q · filed 2025-08-01 | $251.80M derived: sum of 3 quarters · filed 2026-02-11 | $360.20M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $60.40M 10-Q · filed 2025-04-25 | $158.90M derived: sum of 2 quarters · filed 2026-02-11 | $267.30M derived: sum of 3 quarters · filed 2026-02-11 | $260.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $98.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $206.90M derived: sum of 2 quarters · filed 2026-02-11 | $199.60M derived: sum of 3 quarters · filed 2026-02-11 | $321.10M 10-K · filed 2026-02-11 |
| 2023-09-30 | $108.40M 10-Q · filed 2024-10-25 | $101.10M derived: sum of 2 quarters · filed 2024-10-25 | $222.60M 10-Q · filed 2024-10-25 | $364.30M derived: sum of 4 quarters · filed 2025-02-07 |
| 2023-06-30 | -$7.30M 10-Q · filed 2024-07-26 | $114.20M 10-Q · filed 2024-07-26 | $255.90M derived: sum of 3 quarters · filed 2025-02-07 | $422.90M derived: sum of 4 quarters · filed 2025-02-07 |
| 2023-03-31 | $121.50M 10-Q · filed 2024-04-26 | $263.20M derived: sum of 2 quarters · filed 2025-02-07 | $430.20M derived: sum of 3 quarters · filed 2025-02-07 | $617.60M derived: sum of 4 quarters · filed 2025-02-07 |
| 2022-12-31 | $141.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-07 | $308.70M derived: sum of 2 quarters · filed 2025-02-07 | $496.10M derived: sum of 3 quarters · filed 2025-02-07 | $686.50M 10-K · filed 2025-02-07 |
| 2022-09-30 | $167.00M 10-Q · filed 2023-10-27 | $354.40M derived: sum of 2 quarters · filed 2023-10-27 | $544.80M 10-Q · filed 2023-10-27 | $622.60M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-06-30 | $187.40M 10-Q · filed 2023-07-28 | $377.80M 10-Q · filed 2023-07-28 | $455.60M derived: sum of 3 quarters · filed 2024-02-14 | $596.30M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-03-31 | $190.40M 10-Q · filed 2023-04-28 | $268.20M derived: sum of 2 quarters · filed 2024-02-14 | $408.90M derived: sum of 3 quarters · filed 2024-02-14 | $550.50M derived: sum of 4 quarters · filed 2024-02-14 |
| 2021-12-31 | $77.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $218.50M derived: sum of 2 quarters · filed 2024-02-14 | $360.10M derived: sum of 3 quarters · filed 2024-02-14 | $508.00M 10-K · filed 2024-02-14 |
| 2021-09-30 | $140.70M 10-Q · filed 2022-10-28 | $282.30M derived: sum of 2 quarters · filed 2022-10-28 | $430.20M 10-Q · filed 2022-10-28 | $465.60M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | $141.60M 10-Q · filed 2022-07-29 | $289.50M 10-Q · filed 2022-07-29 | $324.90M derived: sum of 3 quarters · filed 2023-02-14 | $266.60M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $147.90M 10-Q · filed 2022-04-29 | $183.30M derived: sum of 2 quarters · filed 2023-02-14 | $125.00M derived: sum of 3 quarters · filed 2023-02-14 | $169.00M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | $35.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | -$22.90M derived: sum of 2 quarters · filed 2023-02-14 | $21.10M derived: sum of 3 quarters · filed 2023-02-14 | $52.00M 10-K · filed 2023-02-14 |
| 2020-09-30 | -$58.30M 10-Q · filed 2021-10-29 | -$14.30M derived: sum of 2 quarters · filed 2021-10-29 | $16.60M 10-Q · filed 2021-10-29 | |
| 2020-06-30 | $44.00M 10-Q · filed 2021-07-30 | $74.90M 10-Q · filed 2021-07-30 | ||
| 2020-03-31 | $30.90M 10-Q · filed 2021-04-28 | |||
| 2019-09-30 | $5.70M 10-Q · filed 2020-10-27 | -$389.60M 10-Q · filed 2020-10-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRUKER CORP (BRKR) | United States | $9.706B | -128.75 |
| REVVITY, INC. (RVTY) | United States | $16.814B | 53.44 |
| Alamar Biosciences, Inc. (ALMR) | United States | $2.300B | |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |